newsfilter
← Latest News
PR Newswire·

New three-year real-world data on Leqembi® presented at CTAD 2026

  • BioArctic AB's partner Eisai presented new real-world results from the LEADER study at the CTAD conference in Boston on November 18, 2026.
  • The analysis of 560 patients across 13 US sites showed a 76% lower rate of progression to moderate or severe Alzheimer's dementia compared with a natural history cohort over 36 months.
  • 81.1% of assessed patients remained stable or improved after an average of 18 months, with 75.8% stable 5.3% improved.
  • 95.0% of all 560 patients were estimated to remain in early Alzheimer's disease stages through three years of treatment.
  • 77% of 43 patients with baseline 5 follow-up amyloid PET scans became amyloid-negative at a median follow-up of 18.1 months.
  • 87.5% of the total study population remained on Leqembi treatment with an average duration of approximately 19 months.
  • Among patients reaching 18 months, 91.7% stayed on therapy; 218 transitioned to every-four-week IV maintenance 64 transitioned to weekly subcutaneous maintenance.
  • 71.1% of patients on monthly IV maintenance 76.6% on weekly subcutaneous maintenance remained stable after roughly 25-26 months.
  • No ARIA events occurred during the subcutaneous maintenance period; isolated ARIA-H was reported in 0.5% of patients during IV maintenance.
  • Clinical outcomes 5 safety profiles were consistent across sexes 5 APOE genotypes 5 concomitant antithrombotic use.
  • A meta-analysis of ~5,000 patients showed a pooled ARIA rate of 12.4% 5 lower than the 21.5% observed in the Phase 3 Clarity AD trial.
  • Symptomatic ARIA was reported in 0.8% of the meta-analysis cohort compared to 2.8% in Clarity AD.
  • Treatment discontinuation due to adverse events was 3.2% in the meta-analysis.
  • Safety findings in LEADER aligned with the ALZ-NET registry 5 US prescribing information for Leqembi.
  • Leqembi is approved in 53 countries 5 under regulatory review in six regions 5 subcutaneous initiation was approved in China 5 Japan in September 2026.
  • BioArctic maintains a collaboration with Eisai 5 which handles global regulatory 5 commercial activities 5 while BioArctic retains rights in the Nordic region.
Company
BioArctic
Keywords
BioArctic